TDC
RGLS

Thompson Davis & Co’s Regulus Therapeutics RGLS Stock Holding History

Thompson Davis & Co’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-146
Closed -$29K – 1157
2017
Q1 		$29K Buy
+146
New +$27.8K 0.04% 365

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Thompson Davis & Co's RGLS Position: Q2 2017 in Review

Thompson Davis & Co sold out of Regulus Therapeutics (RGLS) in Q2 2017, closing a stake of 146 shares — an estimated $29K sold.

Thompson Davis & Co first reported a position in RGLS in Q1 2017 and held it in 1 quarter. The position peaked at $29K in Q1 2017. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2017.

  • Thompson Davis & Co reported no remaining Regulus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 146 Regulus Therapeutics shares in Q2 2017, an estimated $29K.
  • Thompson Davis & Co first reported a position in Regulus Therapeutics in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Regulus Therapeutics position peaked at $29K in Q1 2017.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.